Delcath's liver cancer drug gains FDA orphan-drug status

09/1/2009 | Reuters · Forbes

The FDA granted Delcath Systems' doxorubicin orphan-drug designation as a treatment for primary liver cancer. The company said it plans to further test doxorubicin with its Percutaneous Hepatic Perfusion drug-delivery technology.

View Full Article in:

Reuters · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT